Long-Term #Antibody Response to Human #Papillomavirus #Vaccines: up to 12 Years Follow-Up in the #Finnish Maternity Cohort (J Infect Dis., abstract)

[Source: Journal of Infectious Diseases, full page: (LINK). Abstract, edited.]

Long-Term Antibody Response to Human Papillomavirus Vaccines: up to 12 Years Follow-Up in the Finnish Maternity Cohort

Hanna Artemchuk, Tiina Eriksson, Mario Poljak, Heljä-Marja Surcel, Joakim Dillner, Matti Lehtinen, Helena Faust

The Journal of Infectious Diseases, jiy545, https://doi.org/10.1093/infdis/jiy545

Published: 18 September 2018




Most cervical cancers are caused by vaccine-preventable infections with human papillomaviruses (HPV). HPV prophylactic vaccines Gardasil™ and Cervarix™ have been widely used for >10 years and are reported to induce high antibody levels. A head-to-head comparison of the antibody responses induced by the two vaccines has been performed only up to 5 years.


Virtually all 3,300 16- to 17-year-old Finnish females, who got one of the two HPV vaccines in phase III licensure trials, consented to registry-based long-term follow-up. Linkage with the Finnish Maternity Cohort found that they donated >2,500 serum samples up to 12 years later. Sera of 337 (38.6%) Gardasil™ and 730 (30.3%) Cervarix™ vaccine recipients were retrieved and HPV type-specific antibody levels were determined using in-house multiplexed heparin-HPV Pseudovirion Luminex assay.


HPV16 and HPV18 antibody levels remained stable and above natural infection-related antibody levels for up to 12 years for most vaccine recipients. The median antibody levels were higher among Cervarix™ recipients 7 to 12 years post vaccination (p<0.0001).


The stability of vaccine-induced antibody levels is in accordance with the high long-term protection reported previously. The differences in antibody levels induced by the two vaccines imply that continued follow-up to identify possible breakthrough cases and estimation of the minimal protective levels of serum antibodies is a research priority.

Human papillomavirus (HPV), HPV vaccine, long-term follow-up, comparison, antibodies, serology, Gardasil™, Cervarix™, Finnish Maternity Cohort (FMC)

Issue Section: Major Article

© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)

Keywords: HPV; Cancer; Vaccines; Finland.


Published by

Giuseppe Michieli

I am an Italian blogger, active since 2005 with main focus on emerging infectious diseases such as avian influenza, SARS, antibiotics resistance, and many other global Health issues. Other fields of interest are: climate change, global warming, geological and biological sciences. My activity consists mainly in collection and analysis of news, public services updates, confronting sources and making decision about what are the 'signals' of an impending crisis (an outbreak, for example). When a signal is detected, I follow traces during the entire course of an event. I started in 2005 my blog ''A TIME'S MEMORY'', now with more than 40,000 posts and 3 millions of web interactions. Subsequently I added an Italian Language blog, then discontinued because of very low traffic and interest. I contributed for seven years to a public forum (FluTrackers.com) in the midst of the Ebola epidemic in West Africa in 2014, I left the site to continue alone my data tracking job.